» Articles » PMID: 11248610

Intravesical Potassium Sensitivity in Patients with Interstitial Cystitis and Urethral Syndrome

Overview
Journal Urology
Specialty Urology
Date 2001 Mar 15
PMID 11248610
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To examine populations with diagnosed clinical interstitial cystitis (IC) and urethral syndrome and normal controls using the potassium sensitivity test (PST), to determine the incidence of PST-provoked pain and/or urgency, and to document the type and location of IC and urethral syndrome pain, association of pain with sexual intercourse, and family history of female urgency/frequency problems.

Methods: The PST and a questionnaire were administered to 466 patients with clinical IC, 116 patients with urethral syndrome, and 42 controls.

Results: The PST was positive in 78% of patients with clinical IC, in 55% of patients with urethral syndrome, and in 0% of the controls. Of the patients with clinical IC, 9% responded to the PST with pain only and 8% with urgency only. Patients with clinical IC reported the pain as dysuria (58%), urethral/vaginal (76%), above the pubic bone (53%), lower abdomen (47%), lower back (35%), vaginal (51%), and inguinal (28%). The results were similar for patients with urethral syndrome. Of the sexually active men and women, 71% with clinical IC and 59% with urethral syndrome reported pain associated with intercourse. Urgency/frequency problems in female relatives were reported by 35% of patients with IC and 33% of those with urethral syndrome.

Conclusions: The significant potassium sensitivity in both patients with clinical IC and those with urethral syndrome and the absence of potassium sensitivity in normal controls indicates that a positive PST suggests the presence of an abnormal bladder epithelium. The lower rate of positive PSTs in patients with urethral syndrome reflects the less severe, more intermittent, nature of the symptoms in urethral syndrome (early IC). Pelvic pain of bladder origin may occur anywhere in the pelvis. Finally, IC appears to have a genetic component.

Citing Articles

Characterization and Therapeutic Potential of Curcumin-Loaded Cerium Oxide Nanoparticles for Interstitial Cystitis Management.

Lin Y, Liang Y, Zhang C, Liu L, Lin F Antioxidants (Basel). 2024; 13(7).

PMID: 39061895 PMC: 11273629. DOI: 10.3390/antiox13070826.


The efficacy and safety of intravesical chondroitin sulphate solution in recurrent urinary tract infections.

RahnamaI M, Javan Balegh Marand A, Roschmann-Doose K, Steffens L, Arendsen H BMC Urol. 2022; 22(1):188.

PMID: 36424583 PMC: 9685912. DOI: 10.1186/s12894-022-01149-7.


Molecular Mechanisms and Key Processes in Interstitial, Hemorrhagic and Radiation Cystitis.

Brossard C, Lefranc A, Pouliet A, Simon J, Benderitter M, Milliat F Biology (Basel). 2022; 11(7).

PMID: 36101353 PMC: 9311586. DOI: 10.3390/biology11070972.


Understanding Molecular Mechanisms and Identifying Key Processes in Chronic Radiation Cystitis.

Brossard C, Lefranc A, Simon J, Benderitter M, Milliat F, Chapel A Int J Mol Sci. 2022; 23(3).

PMID: 35163758 PMC: 8836784. DOI: 10.3390/ijms23031836.


Prevalence of Bladder Pain Syndrome-like Symptoms: a Population-based Study in Korea.

Lee J, Yoo K, Choi H J Korean Med Sci. 2021; 36(46):e293.

PMID: 34845871 PMC: 8629718. DOI: 10.3346/jkms.2021.36.e293.